New draft guidance for the development of drugs targeting the early stages of Alzheimer's disease will assist drugmakers with the design of clinical trials aimed at detecting disease before the onset of dementia, said Dr. Paul Aisen, director of the Alzheimer's Disease Cooperative Study. "I think this will be hugely useful to the pharmaceutical industry," he said.

Related Summaries